Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

S Sundar; D K More; M K Singh; V P Singh; S Sharma; A Makharia; P C Kumar; H W Murray

doi:10.1086/318121

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

Clin Infect Dis. 2000 Oct;31(4):1104-7. doi: 10.1086/318121.

Authors

S Sundar¹, D K More, M K Singh, V P Singh, S Sharma, A Makharia, P C Kumar, H W Murray

Affiliation

¹ The Kala-Azar Medical Research Center, Banaras Hindu University Institute of Medical Sciences, Varanasi, India. shyams@nde.vsnl.net.in

PMID: 11049798
DOI: 10.1086/318121

Abstract

In India, 320 patients with visceral leishmaniasis (209 in the state of Bihar and 11 in the neighboring state of Uttar Pradesh) received identical pentavalent antimony (Sb) treatment. Sb induced long-term cure in 35% (95% confidence interval [CI], 28%-42%) of those in Bihar versus 86% (95% CI, 79%-93%) of those in Uttar Pradesh. In Bihar, the center of the Indian epidemic, traditional Sb treatment should be abandoned.

Publication types

Clinical Trial
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Antimony Sodium Gluconate / therapeutic use*
Antiprotozoal Agents / therapeutic use*
Child
Child, Preschool
Disease Outbreaks*
Female
Humans
India / epidemiology
Infant
Leishmaniasis, Visceral / drug therapy*
Leishmaniasis, Visceral / epidemiology*
Male
Middle Aged
Treatment Failure

Substances

Antiprotozoal Agents
Antimony Sodium Gluconate